<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0518C2CF-1198-483C-9D01-D6ACE512823A"><gtr:id>0518C2CF-1198-483C-9D01-D6ACE512823A</gtr:id><gtr:name>nanoTherics Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:department>Inst for Science and Tech in Medicine</gtr:department><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0518C2CF-1198-483C-9D01-D6ACE512823A"><gtr:id>0518C2CF-1198-483C-9D01-D6ACE512823A</gtr:id><gtr:name>nanoTherics Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FA17C03C-E352-46B8-9A28-FA04AA977E51"><gtr:id>FA17C03C-E352-46B8-9A28-FA04AA977E51</gtr:id><gtr:firstName>Jon</gtr:firstName><gtr:surname>Dobson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701054"><gtr:id>51BE6487-D1AF-49B0-9902-E5B5A91DC062</gtr:id><gtr:title>Development of an improved system for magnetic nanoparticle-based gene transfection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701054</gtr:grantReference><gtr:abstractText>With the sequencing of the human genome and the advent of gene therapy has come the need to develop effective delivery and transfection agents. These agents must be able to target therapeutic genes to the relevant cells and organs both in culture for basic investigations as well as in the body for therapeutic applications.

At present, there is a great need for the development of gene carriers which do not use attenuated viruses as a vehicle. We propose to develop such a carrier system based on coupling the genes to magnetic nanoparticles. This will allow us to use oscillating magnetic fields to target, improve and enhance gene delivery both in culture and in the clinic.</gtr:abstractText><gtr:technicalSummary>In order to investigate the role of specific genes in cellular function and to develop new gene therapies, it is necessary to insert ( transfect ) the gene in question into mammalian cells such that it can direct protein expression. This can be achieved via a variety of techniques, the most effective of which are based upon attenuated viral vectors that offer high level transduction of the target gene. 

Recently, however, there has been a great deal of research aimed at the development of non-viral vectors for gene transfer, such as electroporation, cationic polymers and lipid-based agents. These techniques are particularly suited to in vitro transfection and, though effective in many cases, there are drawbacks. Cell viability can be adversely affected by electroporation techniques and there are also difficulties transfecting primary cells and some cell lines as well as tissue explants. In addition, most of these techniques are not suited to in vivo gene therapy due to toxicological issues or poor efficacy.

We propose to develop novel, non-viral transfection techniques that can overcome many of these drawbacks and lead to higher levels of gene transfection, the ability to transfect non-dividing and primary cells and tissue explants with little or no effect on cell viability. The technique is based on coupling the genes to be investigated to biocompatible magnetic nanoparticles and using oscillating magnet arrays to physically force the gene/particle complex into the cell. This development of this physical method should also have clinical application for targeted gene delivery, in much the same way that magnetic nanoparticle targeting is being investigated for drug delivery, and transfection in diseases such as Cystic Fibrosis where the technique may provide a mechanism for overcoming a difficult physical barrier to transfection ? bacterially infected mucous.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-11</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-05-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>220931</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>nanoTherics Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Industrial Collaboration</gtr:description><gtr:id>FCFF7F11-8B3F-46AB-B743-71860FD3952B</gtr:id><gtr:impact>nanoTherics has raised over &amp;pound;1.5 million in equity funding and grants to pursue this work further.</gtr:impact><gtr:outcomeId>nc3HxR2Kare-1</gtr:outcomeId><gtr:partnerContribution>Providing facilities and expertise to progress the research.</gtr:partnerContribution><gtr:piContribution>The work from this project is being commercialized in part by a spin-off company, nanoTherics Ltd.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The use of high-field, high-gradient Halbach arrays in an addressable format. Though the patent was filed before this work began, work on this project contributed to the data used to pursue the patent and overcome examiner objections.</gtr:description><gtr:grantRef>G0701054</gtr:grantRef><gtr:id>AE59D008-C462-40E6-92AE-25CD25E29F44</gtr:id><gtr:impact>Highly efficient and cost-effective transfection technology</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>BFLpPwm33wa</gtr:outcomeId><gtr:patentId>WO2009034319</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Halbach Array for nanomagnetic transfection</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The oscillating field nanomagnetic transfection technology is being commercialized by nanoTherics.</gtr:description><gtr:id>9FF8E7BE-09EE-44ED-BF05-4BEBDAC9F783</gtr:id><gtr:impact>Growing world-wide sales and significant (&amp;gt;&amp;pound;1.5 million) equity funding.</gtr:impact><gtr:outcomeId>UbHyDpdHtpd</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>magnefect</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The nanomagnetic gene transfection technology partially developed in this project is being commercialized by nanoTherics Limited.</gtr:description><gtr:id>4978CD50-C6D6-4BDD-BE4E-10DEC50E5481</gtr:id><gtr:impact>The technology is being used by numerous groups around the world now, including the Neuroscience Department at Johns Hopkins University for specific transfection applications related to neurological disorders and infecdtions.</gtr:impact><gtr:outcomeId>pkbBTsCKTGR</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Gene Transfection System</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>nanoTherics Ltd</gtr:companyName><gtr:description>NanoTherics is developing and commercialising magnetic nanoparticle based products. These include novel gene and small molecule transfection technologies to facilitate research and development in gene-related diseases and disorders. 
www.nanotherics.com</gtr:description><gtr:id>434B912F-193E-4CD8-8568-9F4037B81C2D</gtr:id><gtr:impact>Growing world-wide sales and &amp;gt;&amp;pound;1.5 million in equity investment.</gtr:impact><gtr:outcomeId>kutcTdwF8BR</gtr:outcomeId><gtr:url>http://www.nanotherics.com/</gtr:url><gtr:yearCompanyFormed>2007</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>7906FF52-24DB-405F-BB52-CFDCC4ED8C96</gtr:id><gtr:title>Evaluation of the magnetic field requirements for nanomagnetic gene transfection.</gtr:title><gtr:parentPublicationTitle>Nano reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f76f8dce61a7680ab85a64e8fabe9b23"><gtr:id>f76f8dce61a7680ab85a64e8fabe9b23</gtr:id><gtr:otherNames>Fouriki A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>2000-5121</gtr:issn><gtr:outcomeId>dQSAfmHJS6f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2580CC92-86CC-4D74-9FF4-D6601D52EAD9</gtr:id><gtr:title>Efficient transfection of MG-63 osteoblasts using magnetic nanoparticles and oscillating magnetic fields.</gtr:title><gtr:parentPublicationTitle>Journal of tissue engineering and regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f76f8dce61a7680ab85a64e8fabe9b23"><gtr:id>f76f8dce61a7680ab85a64e8fabe9b23</gtr:id><gtr:otherNames>Fouriki A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6254</gtr:issn><gtr:outcomeId>YrEko5nLHmQ</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701054</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8EA3EC93-8E9C-482F-8121-C6C8413D9B6D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.3  Chemical and physical sciences</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>